All Stories

  1. “Landscape of Phase 2 Trials in Alzheimer’s Disease”: Perspective on Adaptive Trials

    Article • Journal of Alzheimer’s Disease, April 2024, IOS Press

    Jeffrey Cummings

  2. Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial

    Article • Journal of Alzheimer’s Disease, October 2021, IOS Press

    Jeffrey Cummings

  3. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer’s Disease

    Article • Journal of Neuropsychiatry, January 2021, American Psychiatric Association

    Jeffrey Cummings